Lilly inks $2.4B cash deal to buy DICE and its immunology pipeline

Eli Lilly is joining the “blistering” pace of M&A this year as it bets $2.4 billion in cash on DICE Therapeutics, a publicly traded biotech with oral IL-17 inhibitors in the clinic.

The Indianapolis-based Big Pharma said Monday morning it would buy the South San…


ADVERTISEMENT — Advertise With Biotech Networks